There are some remissions, but peripheral neuropathy casts a long shadow.
Evorpacept adds a solid tumour setback to last week’s disappointment in blood cancers, and the CD47 bubble deflates.
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
Transcatheter technologies could be the future – but a distant one.
The focus now falls on first-line melanoma data with bempegaldesleukin plus Opdivo, due in early 2022.
The early movers could point to a disappointing meeting.
Positive phase 2 data with the group’s maternal RSV vaccine set up a busy 2022 for work on the infectious disease.
A high dose of AXO-AAV-GM1 impresses, but small patient numbers provide a reason for caution.
Merus regains some lost pride while Bicycle rides to even greater heights.